NYSE:ENFN Enfusion (ENFN) Stock Price, News & Analysis → A new way to collect income from stocks (From DTI) (Ad) Free ENFN Stock Alerts $9.23 -0.01 (-0.11%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$9.22▼$9.3750-Day Range$8.18▼$9.6652-Week Range$7.37▼$11.56Volume239,894 shsAverage Volume285,494 shsMarket Capitalization$1.18 billionP/E Ratio115.39Dividend YieldN/APrice Target$9.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Enfusion alerts: Email Address Enfusion MarketRank™ Stock AnalysisAnalyst RatingReduce1.67 Rating ScoreUpside/Downside1.1% Upside$9.33 Price TargetShort InterestHealthy4.93% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingSelling Shares$1,179 Sold Last QuarterProj. Earnings Growth142.86%From $0.07 to $0.17 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.62 out of 5 starsComputer And Technology Sector465th out of 592 stocksPrepackaged Software Industry169th out of 201 stocks 0.8 Analyst's Opinion Consensus RatingEnfusion has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on 1 buy rating, 2 hold ratings, and 3 sell ratings.Amount of Analyst CoverageEnfusion has only been the subject of 3 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.93% of the float of Enfusion has been sold short.Short Interest Ratio / Days to CoverEnfusion has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in Enfusion has recently decreased by 25.17%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldEnfusion does not currently pay a dividend.Dividend GrowthEnfusion does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ENFN. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Enfusion this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for ENFN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Enfusion insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,179.00 in company stock.Percentage Held by Insiders39.18% of the stock of Enfusion is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions81.05% of the stock of Enfusion is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Enfusion are expected to grow by 142.86% in the coming year, from $0.07 to $0.17 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enfusion is 115.39, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 142.49.Price to Earnings Ratio vs. SectorThe P/E ratio of Enfusion is 115.39, which means that it is trading at a less expensive P/E ratio than the Computer and Technology sector average P/E ratio of about 245.03.Price to Earnings Growth RatioEnfusion has a PEG Ratio of 2.69. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioEnfusion has a P/B Ratio of 15.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIA new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. About Enfusion Stock (NYSE:ENFN)Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. It also offers Accounting/General Ledger System, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion Analytics System, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. Enfusion, Inc. was founded in 1997 and is headquartered in Chicago, Illinois.Read More ENFN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ENFN Stock News HeadlinesApril 18, 2024 | businesswire.comEnfusion Announces Date of First Quarter 2024 ResultsApril 17, 2024 | morningstar.comEnfusion Inc Class AApril 23, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… April 12, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Enfusion, Inc. - ENFNApril 4, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Enfusion, Inc. - ENFNApril 4, 2024 | msn.comThe 3 Most Undervalued Under-$10 Stocks to Buy in April 2024April 2, 2024 | finance.yahoo.comWill Enfusion (ENFN) Grow Revenue And Expand Margins In The Future?April 2, 2024 | businesswire.comConnexPay Appoints Ben Peters as Chief Executive OfficerApril 23, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… March 27, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Enfusion, Inc. - ENFNMarch 22, 2024 | markets.businessinsider.comEnfusion’s Growth Strategy Met with Sell Rating Amid Market and Strategic ChallengesMarch 21, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Technology Stocks: GoDaddy (GDDY) and Enfusion (ENFN)March 20, 2024 | markets.businessinsider.comStifel Nicolaus Keeps Their Buy Rating on Enfusion (ENFN)March 19, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Enfusion, Inc. - ENFNMarch 15, 2024 | markets.businessinsider.comWall Street Favorites: 3 Under-$10 Stocks with Strong Buy Ratings for March 2024March 14, 2024 | seekingalpha.comEnfusion, Inc. (ENFN) Q4 2023 Earnings Call TranscriptMarch 14, 2024 | finance.yahoo.comEnfusion, Inc. (NYSE:ENFN) Q4 2023 Earnings Call TranscriptMarch 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Technology Companies: Copperleaf Tech (OtherCPLFF), Rackspace Technology (RXT) and Enfusion (ENFN)March 12, 2024 | markets.businessinsider.comWilliam Blair Reaffirms Their Buy Rating on Enfusion (ENFN)March 12, 2024 | msn.comEnfusion reports mixed Q4 results; initiates FY24 outlookMarch 12, 2024 | finance.yahoo.comEnfusion Announces Fourth Quarter 2023 Results and Full Year 2023 ResultsMarch 11, 2024 | benzinga.comEarnings Outlook For EnfusionMarch 6, 2024 | benzinga.comMajor Purchase Alert: Oleg Movchan Invests $120K In Enfusion StockFebruary 29, 2024 | msn.comGoldman Sachs Downgrades Enfusion (ENFN)February 28, 2024 | msn.comEnfusion stock retreats after Goldman downgrades to SellFebruary 28, 2024 | markets.businessinsider.comEnfusion Stock Sell Rating: Conservative Revenue Growth and Market Challenges AheadFebruary 20, 2024 | msn.comArteris, Inc. (AIP) Reports Q4 Loss, Tops Revenue EstimatesSee More Headlines Receive ENFN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enfusion and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/12/2024Today4/23/2024Next Earnings (Confirmed)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorComputer and Technology Industry Prepackaged software Sub-IndustryN/A Current SymbolNYSE:ENFN CUSIPN/A CIK1868912 Webwww.enfusion.com Phone312-253-9800FaxN/AEmployees1,102Year FoundedN/APrice Target and Rating Average Stock Price Target$9.33 High Stock Price Target$11.00 Low Stock Price Target$8.00 Potential Upside/Downside+1.1%Consensus RatingReduce Rating Score (0-4)1.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)$0.08 Trailing P/E Ratio115.39 Forward P/E Ratio131.86 P/E Growth2.69Net Income$6.03 million Net Margins3.45% Pretax Margin6.58% Return on Equity10.30% Return on Assets7.78% Debt Debt-to-Equity RatioN/A Current Ratio3.44 Quick Ratio3.44 Sales & Book Value Annual Sales$174.54 million Price / Sales6.77 Cash Flow$0.14 per share Price / Cash Flow64.11 Book Value$0.61 per share Price / Book15.13Miscellaneous Outstanding Shares128,070,000Free Float77,892,000Market Cap$1.18 billion OptionableOptionable Beta1.00 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Oleg Movchan (Age 49)CEO & Director Comp: $876.34kMr. Bradley Herring (Age 53)Chief Financial Officer Comp: $267.05kMs. Bronwen Bastone (Age 51)Chief People Officer Comp: $566.25kMr. Stephen MalherbeManaging PartnerMr. Neal PawarChief Operating OfficerMs. Valeria Gutowski (Age 42)Chief Accounting Officer Mr. Daniel Groman (Age 35)Chief Technology Officer Mr. Ignatius Tochukwu NjokuHead of Investor RelationsMatt CampobassoGeneral CounselMr. Joseph DefeoGlobal Head of Managed Services ProductionMore ExecutivesKey CompetitorsCouchbaseNASDAQ:BASEPDF SolutionsNASDAQ:PDFSZuoraNYSE:ZUOSoundHound AINASDAQ:SOUNHello GroupNASDAQ:MOMOView All CompetitorsInsiders & InstitutionsWasatch Advisors LPBought 201,771 shares on 4/18/2024Ownership: 0.618%Allspring Global Investments Holdings LLCBought 4,772 shares on 4/18/2024Ownership: 0.004%Wellington Management Group LLPBought 26,464 shares on 3/5/2024Ownership: 0.384%Matthew CampobassoSold 108 sharesTotal: $942.84 ($8.73/share)Valeria GutowskiSold 27 sharesTotal: $235.71 ($8.73/share)View All Insider TransactionsView All Institutional Transactions ENFN Stock Analysis - Frequently Asked Questions Should I buy or sell Enfusion stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Enfusion in the last year. There are currently 3 sell ratings, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "reduce" ENFN shares. View ENFN analyst ratings or view top-rated stocks. What is Enfusion's stock price target for 2024? 6 Wall Street analysts have issued 12 month target prices for Enfusion's stock. Their ENFN share price targets range from $8.00 to $11.00. On average, they anticipate the company's share price to reach $9.33 in the next year. This suggests a possible upside of 1.1% from the stock's current price. View analysts price targets for ENFN or view top-rated stocks among Wall Street analysts. How have ENFN shares performed in 2024? Enfusion's stock was trading at $9.70 at the beginning of the year. Since then, ENFN shares have decreased by 4.8% and is now trading at $9.23. View the best growth stocks for 2024 here. Are investors shorting Enfusion? Enfusion saw a decrease in short interest during the month of March. As of March 31st, there was short interest totaling 2,260,000 shares, a decrease of 25.2% from the March 15th total of 3,020,000 shares. Based on an average daily volume of 409,100 shares, the short-interest ratio is presently 5.5 days. Approximately 4.9% of the company's stock are short sold. View Enfusion's Short Interest. When is Enfusion's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ENFN earnings forecast. How can I listen to Enfusion's earnings call? Enfusion will be holding an earnings conference call on Thursday, May 9th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link. How were Enfusion's earnings last quarter? Enfusion, Inc. (NYSE:ENFN) released its quarterly earnings data on Tuesday, March, 12th. The company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.03 by $0.02. The business earned $46.49 million during the quarter, compared to analyst estimates of $45.56 million. Enfusion had a net margin of 3.45% and a trailing twelve-month return on equity of 10.30%. What guidance has Enfusion issued on next quarter's earnings? Enfusion updated its FY 2024 earnings guidance on Tuesday, March, 12th. The company provided EPS guidance of for the period. The company issued revenue guidance of $200.0 million-$210.0 million, compared to the consensus revenue estimate of $202.3 million. When did Enfusion IPO? Enfusion (ENFN) raised $300 million in an IPO on Thursday, October 21st 2021. The company issued 18,750,000 shares at $15.00-$17.00 per share. Who are Enfusion's major shareholders? Enfusion's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wasatch Advisors LP (0.62%) and Allspring Global Investments Holdings LLC (0.00%). Insiders that own company stock include Bradley Herring, Bronwen Bastone, Dan Groman, Deirdre Somers, Hillhouse Investment Managemen, Matthew Campobasso, Oleg Movchan, Roy Luo, Stephen Malherbe, Tarek Hammoud and Valeria Gutowski. View institutional ownership trends. How do I buy shares of Enfusion? Shares of ENFN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:ENFN) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe #1 Crypto for 2024InvestorPlaceGreat Crypto BullWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enfusion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
